Diadexus, Inc. Stock

DDXSQ

US25245P2056

Pharmaceuticals

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

17/09/21	Diadexus, Inc. Went Out of Business	CI
08/06/18	Motion for Asset Sale Approved for Diadexus, Inc.	CI

Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	49.2K 43.18K 40.21K 36.98K 69.32K 4.7M 70.51K 477K 187K 2.33M 185K 181K 8.05M	P/E 2014	-3.26x	P/E 2015	-1.14x
Enterprise Value	5.29M 4.64M 4.32M 3.98M 7.45M 505M 7.58M 51.29M 20.08M 251M 19.86M 19.43M 866M	EV / Sales 2014	1.05x	EV / Sales 2015	0.77x
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

17/09/21	Diadexus, Inc. Went Out of Business	CI
08/06/18	Motion for Asset Sale Approved for Diadexus, Inc.	CI
09/05/18	Motion for Asset Sale Filed by Diadexus, Inc.	CI
01/08/16	Diazyme Laboratories, Inc. completed the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
29/07/16	Motion for Asset Sale Approved for Diadexus, Inc.	CI
29/07/16	General Atomics Corp. entered into purchase agreement to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $4.8 million.	CI
20/07/16	Cleveland HeartLab, Inc. cancelled the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
07/07/16	Motion for Asset Sale Filed by Diadexus, Inc.	CI
07/07/16	Cleveland HeartLab, Inc. agreed to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $7 million.	CI
13/06/16	Diadexus, Inc. Filed for Bankruptcy	CI
11/06/16	Diadexus, Inc. Announces Resignation of Leone Patterson as Chief Financial Office	CI
23/05/16	Diadexus, Sonic Healthcare USA Sign National Agreement for PLAC Activity Test	CI
30/04/16	Diadexus, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIADEXUS, INC.	-.--%	-.--%	-	-	410
ULTRAGENYX PHARMACEUTICAL INC.	-3.70%	-9.96%	-6.66%	-40.22%	2.64B
SAREPTA THERAPEUTICS, INC.	-3.15%	-5.73%	+10.26%	-85.92%	1.68B
BIONOTE, INC.	-4.86%	-3.40%	-16.41%	-22.31%	319M
DK LIFE SCIENCE CO., LTD.	-2.70%	+1.74%	-52.14%	-	52.49M
Average	-2.87%	-2.05%	-16.24%	-49.48%	937.9M
Weighted average by Cap.	-3.55%	-5.20%	-1.78%	-55.52%

	2014	2015
Net sales	26.11M 22.92M 21.34M 19.63M 36.79M 2.49B 37.42M 253M 99.09M 1.24B 98.03M 95.91M 4.27B	17.88M 15.69M 14.62M 13.44M 25.2M 1.71B 25.63M 173M 67.87M 847M 67.14M 65.69M 2.93B
Net income	-8.47M -7.43M -6.92M -6.36M -11.93M -809M -12.13M -82.09M -32.13M -401M -31.79M -31.1M -1.39B	-7.17M -6.29M -5.86M -5.39M -10.1M -685M -10.27M -69.48M -27.19M -340M -26.9M -26.32M -1.17B
Net Debt	-198K -174K -162K -149K -279K -18.92M -284K -1.92M -751K -9.38M -743K -727K -32.41M	5.24M 4.6M 4.28M 3.94M 7.38M 501M 7.51M 50.81M 19.89M 248M 19.68M 19.25M 858M

Diadexus, Inc. Stock

Stocks

DDXSQ

US25245P2056

Pharmaceuticals

Valuation: Diadexus, Inc.

Latest news : Diadexus, Inc.

Diagnostic & Testing Substances Manufacturers

Financials

Company Profile